- Article
- Source: Campus Sanofi
- 23 Oct 2023
T1 Edition Junior Study
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/Hero/header-3.jpg/jcr:content/header-3.jpg)
Prescribing Information Toujeo (insulin glargine 300 units/mL)
Prescribing Information Lantus (insulin glargine 100 units/mL)
![toujeo logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/Image/toujeo-content-page-logo2--2-.jpg/jcr:content/toujeo-content-page-logo2%20(2).jpg)
Ask us your questions about our products, patient materials or organising a meeting.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/t1-junior-summary/Image/Junior_updated_nov22.jpg/jcr:content/Junior_updated_nov22.jpg)
Edition Junior
Download this clinical summary to read about the benefits of Toujeo® in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL from baseline to Week 26.
MAT-XU-2205630 (v5.0) Date of Preparation: October 2023